Supplementary Table 1: Summary of alternative methods for immunogen production for anti-HIV vaccines.

| Ref. | pVL required to start HIV-1 isolation (RNA copies /mL) | Virus origin and spread | Time in culture (days) | HIV-1 Production (RNA copies /mL) |
|------------|--|--|------------------------|--------------------------------------|
| 14 | ≥ 10000 | Heterologous | 30 | 2x10 ⁹ |
| | | Coculture of CD4+ T cells | | |
| 15 | > 5000 | Plasmaphereses | 1 | 7,4x10 ⁸ |
| 16 | ≥ 50000 | Leukaphereses | 42-56 | 6x10 ⁹ |
| | | Superinfection of CD4+ enriched T cells from one healthy | | |
| | | donor with autologous HIV-1 (Endogenous virus was | | |
| | | isolated from peripheral blood-derived CD4+ T cells). | | |
| 17; 29; 13 | ≥ 10000 | 150 mL peripheral blood | 28 | 1.9x10 ⁹ |
| | | Heterologous coculture of CD4+ cells | | |
| 18 | Median 26225 | Leukaphereses | 36-55 | 4x10 ⁹ |
| | (486-1860000) | Autologous culture of CD4+ cells | | |
| This | >5000 | 100 mL peripheral blood | 20 | 4,7x10 ¹⁰ |
| manuscript | | Autologous coculture of CD14+ and CD4 + cells | | |